Orladeyo (berotralstat) is FDA indicated to treat Hereditary Angioedema
… FDA Approves Orladeyo (berotralstat) for Hereditary Angioedema patients …

Orladeyo (berotralstat) by BioCryst Pharmaceuticals Earns FDA Approval

A new cardiovascular agent treats Hereditary Angioedema (HAE)

Orladeyo’s oral formulation is a competitive advantage

  • Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]) is made by CSL Behring GmbH (ASX: CSL) and was approved by the FDA in 2017
  • Takhzyro (lanadelumab-flyo) is a monoclonal antibody (mAb) marketed by Takeda (NYSE: TAK) that was issued FDA approval in 2018

Orladeyo’s oral formulation is an added element to its market access strategy

BioCryst is a compact, R&D-focused biopharmaceutical enterprise

The FDA has been on a roll with evaluating advanced new therapies for rare diseases and improving their availability to patients and medical professionals

--

--

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Bare Sky Marketing — Healthcare Content Writing

Authentic, fact-based healthcare content marketing writing for medical, business, academic, patient and consumer audiences https://www.BareSkyMarketing.com/